One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
GH Research PLC
GHRS · NGM · Healthcare · Biotechnology
Current price
$18.15
52-week range
$12.04 - $31.44
Market cap
$1.25B
Balance sheet
Healthy
-1,733.60x Concerning
Net cash $362.29M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
GH Research PLC
GH Research PLC is a company working on new medicines to help people with depression. Their main focus is on a treatment called GH001, which is inhaled, and they are testing it in patients who haven't gotten better with other treatments. This matters because if their medicine works, it could offer a new option for a widespread and challenging condition.
How the company got here
GH Research PLC was founded in 2018 with the goal of developing new treatments for serious mental health conditions. The company is focused on a specific type of drug called mebufotenin, which it is investigating for its potential to treat depression and other mood disorders. Its journey so far has involved progressing these drug candidates through various stages of clinical trials to test their safety and effectiveness in humans.
What it actually does
GH Research PLC is a biopharmaceutical company that is working on developing medicines, primarily for depression. It's still in the 'clinical-stage,' meaning its drugs are not yet approved for sale and are being tested in people. The company's main focus is on a compound called mebufotenin, which it is exploring in different forms and delivery methods to treat various forms of depression and related conditions.
GH001 (Inhalable Mebufotenin)
This is GH Research's main product candidate, which involves a form of mebufotenin that patients can inhale, like using an inhaler. It is currently being tested in Phase 2b clinical trials, which are designed to see if the drug works for people with depression that hasn't responded to other treatments. The company is also exploring its use in Phase 2a trials for conditions like bipolar II disorder and postpartum depression. This business line represents the company's most advanced effort to bring a new depression treatment to market.
GH002 (Intravenous Mebufotenin)
GH002 is another product candidate from GH Research, but this one is designed to be given through an IV (intravenous) infusion, directly into the bloodstream. This candidate is in an earlier stage of testing, a Phase 1 clinical pharmacology trial, which is primarily focused on understanding how the drug works in the body and its safety in healthy volunteers. The company is investigating its potential for psychiatric and neurological disorders, indicating a broader scope than just depression.
What management is betting on now
GH Research's core strategy revolves around advancing its mebufotenin-based drug candidates through the rigorous clinical trial process. The company is heavily invested in demonstrating the efficacy and safety of both its inhalable (GH001) and intravenous (GH002) forms of mebufotenin. Success in these trials is crucial for seeking regulatory approval and eventually bringing these novel treatments to patients suffering from difficult-to-treat depression and other mood disorders.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $18.15
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $362.3M - more cash than debt. Interest coverage -1733.6x.
Net debt
$-362.29M
Interest coverage
-1,733.60x
GH Research PLC's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
GHRS
BASELINE
GH Research PLC
Total debt $360.00K Interest coverage -1,733.60x This is the baseline the peer rows are being compared against.
Total debt $36.47M Interest coverage -30.34x Neither company has much profit cushion over interest right now.
Total debt $509.00M Interest coverage 5.89x This peer still has a real interest-payment cushion, while GHRS does not.
Total debt $8.55B Interest coverage 2.43x This peer still has a real interest-payment cushion, while GHRS does not.
What you should know
The case for and against GHRS
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -18.8% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-9.81x
P/B
3.47x
P/S
—
EV/EBITDA
-13.02x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-18.8%
ROA
-13.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
28.70x
Quick ratio
28.21x
Total debt
$360.00K
Total cash
$362.65M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.99
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-43.55M
Free CF TTM
$-43.67M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—